Highlights
• AusCann appoints TGA licensed PCI Pharma to manufacture and release its first medicinal cannabis product line.
• New proprietary solid hard shell capsules for treatment of chronic pain are scheduled for release in H1 2019.
• AusCann’s first stage solid capsule product addresses the needs of doctors and patients for a consistent, stable, easy to administer oral dose form for the treatment of chronic pain.
• Initial target market is the estimated 1.9 million Australians who suffer chronic neuropathic pain through the TGA’s Special Access Scheme.
Tuesday, 13 November 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to announce it has appointed TGA licensed PCI Pharma to manufacture and release its first medicinal cannabis product line, its proprietary solid hard shell capsules for treatment of chronic pain. These products are scheduled for release in H1 2019.
For further information please download PDF attached:
Download this document
